Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Top Cited Papers
- 20 July 2008
- journal article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 26 (8), 925-932
- https://doi.org/10.1038/nbt.1480
Abstract
Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs. However, conventional drug conjugation strategies yield heterogenous conjugates with relatively narrow therapeutic index (maximum tolerated dose/curative dose). Using leads from our previously described phage display-based method to predict suitable conjugation sites, we engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb immunoglobulin folding and assembly, or alter antigen binding. When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models. Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepared by conventional approaches. The favorable in vivo properties of the near-homogenous composition of this conjugate suggest that our strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.Keywords
This publication has 32 references indexed in Scilit:
- Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor ModelsCancer Research, 2007
- Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target AntigenCancer Research, 2006
- CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.Clinical Cancer Research, 2006
- Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicityBioconjugate Chemistry, 2005
- Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometryProtein Science, 2005
- Arming antibodies for cancer therapyCurrent Opinion in Pharmacology, 2005
- Drug-conjugated monoclonal antibodies for the treatment of cancerCurrent Opinion in Pharmacology, 2005
- A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate CancerCancer Research, 2004
- Site-specific Conjugation on Serine → Cysteine Variant Monoclonal AntibodiesJournal of Biological Chemistry, 2000
- Site-specific attachment to recombinant antibodies via introduced surface cysteine residuesProtein Engineering, Design and Selection, 1990